Traumatic brain injuries are a very common injury, accounting for approximately 30 percent of all deaths from injury in the United States. Severe traumatic brain injuries that don’t result in death are a common cause of disability, including a number of long-term disabilities.
According to the Centers for Disease Prevention and Control, traumatic brain injuries are so prevalent that every day, 138 people in the United States will die as a result of an injury that includes a traumatic brain injury.
Given the prevalence of traumatic brain injuries, the effectiveness of treatment options available to patients is an important issue. A recent study has found, however, that one common treatment for traumatic brain injury – platelet transfusion and the administration of DDAVP (desmopressin) – is not effective in either preventing hemorrhage in the brain or in reducing the risk of death.
The study was a three-year retrospective study which looked at 408 patients with traumatic brain injury. One hundred and twenty-six of these patients received platelet transfusion and DDAVP as a therapy, while the remaining 282 patients didn’t.
When the outcomes of both groups of patients were compared, there was no significant difference in either patient mortality or in the prevention of intercranial bleeding in both groups. Because potential complications are associated with platelet transfusion, the study’s researchers suggest that the necessity of using such a treatment should be reconsidered by doctors when treating patients with traumatic brain injuries.
If you or someone you love has been injured in an accident, Bradley I. Kramer and his experienced legal team are here to help you obtain the compensation to which you are entitled. Contact us today to schedule your free consultation.